fusion inhibitor


Also found in: Medical, Wikipedia.
Related to fusion inhibitor: protease inhibitor, Integrase inhibitor

fusion inhibitor

n.
Any of a class of drugs that interfere with the entry of HIV into helper T cells by inhibiting the fusion of the viral and cell membranes.
Mentioned in ?
References in periodicals archive ?
Joseph M Patti, PhD, president and chief executive officer of Aviragen Therapeutics, said, 'We are thrilled to begin this collaboration with Dr Plemper as we broaden our internal efforts to develop RSV non-fusion inhibitor compounds to complement BTA585, our fusion inhibitor currently in a Phase 2a clinical trial.
Their topics include a critical academic perspective on marketing antimicrobial peptides, conotoxin-based leads in drug design, kyotorphin derivatives as an example of turning endogenous peptides into new analgesics, sifuvirtide as a novel HIV-1 fusion inhibitor, translational research on amylin agonism, and developing antibody fragments for therapeutic applications.
To potently inhibit HIV-1 entry, a C-HR targeting fusion inhibitor can have a relatively low affinity, but an N-HR targeting fusion inhibitor must bind extremely tightly.
IPF has demonstrated to have both fusion inhibitor and immunomodulator capabilities during in vitro studies with no viral resistance.
In January, new precautions were added to the labeling for the injectable HIV fusion inhibitor Fuzeon.
The fusion inhibitor already on the market--enfuvirtide, developed in 2003 by Roche and Trimeris under the brand name Fuzeon--has proven effective, but many HIV-positive patients are turned off by its high cost and the fact that it must be injected with a syringe.
Under a range of assumptions about drug costs, the efficacy of therapy and the availability of a fusion inhibitor (a drug that prevents HIV from entering healthy cells), the current estimated life expectancy varied from 21 to 25 years, and discounted lifetime cost varied from about $330,000 to $400,000.
The approval of the protease inhibitor darunavir and the fusion inhibitor enfuviritide .
The approval of the fusion inhibitor T-20 (enfuvirtide, Fuzeon) now means that there are 4 classes of drugs available.
reports that ample supplies of the product, also known as enfuvirtide, enable expanded distribution of the drug, the first fusion inhibitor for the treatment of HIV.
T-1249 is a next generation T-20-like peptide fusion inhibitor that retains activity against T-20-resistant HIV-1.
The FDA granted accelerated approval to the first fusion inhibitor to treat HIV-1 in adults and children over 6.